|1.||Danysz, Wojciech: 5 articles (12/2008 - 04/2006)|
|2.||Sadler, Peter J: 4 articles (12/2015 - 12/2006)|
|3.||Lee, Eung-Seok: 4 articles (10/2015 - 01/2010)|
|4.||Na, Younghwa: 4 articles (10/2015 - 01/2010)|
|5.||Thapa, Pritam: 4 articles (10/2015 - 01/2010)|
|6.||Kwon, Youngjoo: 4 articles (10/2015 - 01/2010)|
|7.||Dekundy, Andrzej: 4 articles (12/2008 - 04/2006)|
|8.||Kung, Mei-Ping: 4 articles (02/2008 - 04/2004)|
|9.||Oh, Chang-Hyun: 3 articles (01/2013 - 08/2011)|
|10.||Karki, Radha: 3 articles (03/2010 - 01/2010)|
|1.||Chronic Kidney Failure (Chronic Renal Failure)
01/01/1988 - "In a double-blind randomized clinical trial the efficacy and safety of oral high-dose torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea, T) therapy was compared with that of furosemide (F) in 10 patients with advanced chronic renal failure. "
01/01/1988 - "In a double-blind, randomised group comparative study the efficacy of daily oral administration of 100 mg and 200 mg torasemide (1-isopropyl-3-([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) were compared with that of 250 mg furosemide over 2 weeks in patients with advanced chronic renal failure, who had been pretreated with a maintenance therapy of 500 mg furosemide per day. "
01/01/1988 - "In a controlled randomized double-blind clinical trial the salidiuretic efficacy of 20 and 100 mg torasemide (1-isopropyl-3-([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) and 60 mg furosemide, respectively, was compared including a control group with placebo after a single i.v. administration in 46 patients with advanced chronic renal failure (creatinine clearance less than or equal to 30 ml/min). "
01/01/1988 - "In a comparative study on the fluid and electrolyte excretion of 90 patients with chronic renal failure (serum creatinine greater than or equal to 3.0 mg/dl) 100 and 200 mg torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) vs. 100 and 200 mg furosemide were administered intravenously. "
01/01/1994 - "Reduced and oxidized glutathione and pyridine coenzymes, glutathione-related enzymes and Cu,Zn-superoxide dismutase (Cu,Zn-SOD) were investigated in the RBC of patients with chronic renal failure (CRF) and in age- and sex-matched controls. "
10/22/2015 - "Synthetic Studies on Centromere-Associated Protein-E (CENP-E) Inhibitors: 2. Application of Electrostatic Potential Map (EPM) and Structure-Based Modeling to Imidazo[1,2-a]pyridine Derivatives as Anti-Tumor Agents."
06/01/2012 - "The objective of the current study was to evaluate the anti cancer activities of a series of four and five-coordinated Pt(II) complexes, having deprotonated 2-phenyl pyridine (abbreviated as C^N), biphosphine moieties, i.e., dppm = bis(diphenylphosphino) methane (Ph(2)PCH(2)PPh(2)) and dppa = bis(diphenylphosphino)amine (Ph(2)PNHPPh(2)), as the non-leaving carrier groups. "
10/20/2015 - "The development of new stable 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-fused chlorins with high absorption properties at 650 nm, and their impressive photosensitizer ability against melanotic and amelanotic cancer cells is described. "
04/01/2015 - "Furthermore, we also demonstrate that 360B, a G-quadruplex ligand of the pyridine derivative series that impairs telomere replication and mitotic progression in cancer cells, prevents the development of TG20 tumors. "
10/15/2014 - "In a direct comparison with known Myc inhibitors using human and avian cell systems, the pyridine compounds reveal a unique inhibitory potential even at sub-micromolar concentrations combined with remarkable specificity for the inhibition of Myc-driven tumor cell proliferation. "
04/01/1958 - "[Study of experimental poisonings by pyridine: effects on growth & basal metabolism; anatomicopathological lesions; localizations & elimination]."
01/01/1973 - "[Therapeutic action of some pyridine series dioximes in experimental O-isopropyl-methyl-fluorophosphonate poisoning]."
04/01/1960 - "[Clinical aspects of acute poisoning with vapors of pyridine bases]."
06/01/1959 - "Protection against lethal organophosphate poisoning by quaternary pyridine aldoximes."
05/01/1983 - "Studies on thiohydroximic thioesters in combination with pyridine aldoximes in acute organophosphorus poisoning."
|4.||Alzheimer Disease (Alzheimer's Disease)
05/01/2006 - "(123)I-IMPY (6-iodo-2-(4'-dimethylamino-)phenyl-imidazo[1,2-a]pyridine) is a novel radiopharmaceutical that selectively binds to Alzheimer's disease (AD) amyloid plaques. "
08/01/1997 - "To investigate whether odor detection sensitivity for pyridine, suggested by previous research not to be affected, is impaired in Alzheimer disease (AD) and whether an association exists between odor threshold and both degree of dementia and rate of dementia progression in AD. "
08/01/1997 - "Olfactory dysfunction for pyridine and dementia progression in Alzheimer disease."
10/20/2015 - "Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease."
01/01/2015 - "In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease."
01/01/2015 - "TBA-354 (SN31354[(S)-2-nitro-6-((6-(4-trifluoromethoxy)phenyl)pyridine-3-yl)methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine]) is a pyridine-containing biaryl compound with exceptional efficacy against chronic murine tuberculosis and favorable bioavailability in preliminary rodent studies. "
09/01/2000 - "Pyridine derivatives have always attracted the interest of research laboratories searching for new chemotherapeutic agents against tuberculosis. "
06/26/2014 - "Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent."
04/01/2012 - "The title compound, C(18)H(27)N(3)O, is a derivative of the anti-tuberculosis drug isoniazid (systematic name: pyridine-4-carbohydrazidei). "
02/01/2005 - "The mechanism of activation thioamide-pyridine anti-tuberculosis prodrugs is poorly described in the literature. "
|5.||metabotropic glutamate receptor 5
|6.||metabotropic glutamate receptor type 1
|2.||Self Administration (Administration, Self)